Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2008
04/16/2008CN100381151C Dermatosis treating Chinese medicine prepn
04/16/2008CN100381150C Composition comprising epalrestat
04/16/2008CN100381137C Wound repairing and burns treating cream
04/16/2008CN100381136C Pharmaceutical composition for treating constipation, its formulation and preparation process thereof
04/16/2008CN100381133C Application of pharmaceutical composition in the process for preparing medicine to treat aspirin resisting disease
04/16/2008CN100381132C Hypoglycemic Chinese medicine prepn and its production process
04/16/2008CN100381126C Treating agent of plant poly pentene alcohol gor liver damage
04/16/2008CN100381125C Cardiac and cerebral vascular disease treating medicinal composition
04/16/2008CN100381124C Magnesium iso-glycyrrhetate gel and its preparing method and use
04/16/2008CN100381123C Granules of clarityne and their production method
04/16/2008CN100381122C Compounding hypotensor contg. amlodipine and atenolol
04/16/2008CN100381121C New use of linolenic acid in preparation of anti arthrolithiasis medicine or health care food
04/16/2008CN100381120C Fibrauretine powder for injection and its production process
04/16/2008CN100381119C Compositions for diabetes
04/16/2008CN100381116C Quisnon dispersion tablet
04/16/2008CN100381063C Preparation method of fat-reducing blood sugar-reducing sour soybean milk containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder
04/16/2008CN100381060C Method for preparing liver-benefiting, face-beautifying yoghout with micron pine pollen, pearl powder for women
04/16/2008CA2683910A1 Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
04/15/2008USRE40246 Method for the suppression of viral growth
04/15/2008USRE40245 Gyrase inhibitors and uses thereof
04/15/2008US7358395 Antagonist of the 5-HT2C receptor; antidepressant; nervous system dosorders; excellent purity; storage stability; crystalline form obtained by high energy mechanical grinding or heating to melt compound and immediately cooling at room temperture; perfectly reproducible for easy dissolution or formulation
04/15/2008US7358390 Polymorphic forms of nateglinide
04/15/2008US7358386 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
04/15/2008US7358376 Substituted Thiophene compounds
04/15/2008US7358374 Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a method for effective purification of racemic lasofoxifene
04/15/2008US7358369 Radiolabelled phenylethyl imidazole carboxylic acid ester derivatives
04/15/2008US7358350 Oncogene, recombinant protein derived therefrom, and uses thereof
04/15/2008US7358346 Synthesis of C-beta-D-xylopyranoside-2-(S)-hydroxypropane or C-beta-D-fucopyranoside-2-(S)-hydroxypropane from C-beta-D-xylopyranoside-2-propanone or c-beta-D-fucopyranoside-2-propanone using sodium borohydride, isopropanol and sodium triacetoxyborohydride; glycosaminoglycans
04/15/2008US7358342 Preparation derived from shark cartilage for treatment of diseased related to excessive PHF or excessive intracellular calcium
04/15/2008US7358341 Secreted protein for use in diagnosis, prevention and treatment of thyroid gland disorders
04/15/2008US7358333 Polypeptides of the IFNα-5 gene
04/15/2008US7358278 Cellular phosphorylation potential enhancing compositions preparation and use thereof
04/15/2008US7358277 an alkali metal or alkaline earth metal lactate salt is useful for simultaneous improvement of the skeleton and/or for the simultaneous prophylaxis and/or treatment of osteoporosis.
04/15/2008US7358276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
04/15/2008US7358275 cloprostenol or latanoprost; topical use; highly crystalline structures that are easy to formulate into ophthalmic solutions; The hydrolysis of these analogs releases only the active PGF2 alpha analog free acid, without the production of toxic and irritant small aliphatic alcohol coproducts
04/15/2008US7358274 Methods for treating or preventing cancer using Benzopyranone Compounds
04/15/2008US7358273 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases
04/15/2008US7358272 Reduction of levels of tumor necrosis factor-alpha and/or inhibition of phosphodiesterase 4; treating cancer, especially various types of leukemia
04/15/2008US7358271 Sulpiride pharmaceutical compositions
04/15/2008US7358270 Treating agent for irritable bowel syndrome
04/15/2008US7358269 selective to alpha2B and/or alpha2C adrenergic receptors, minimal cardivascular and/or sedatory activity; pain
04/15/2008US7358268 Imidazole derivatives as factor Xa inhibitors
04/15/2008US7358267 2-(pyrazol-1-yl)thiazole compounds; obesity and type II diabetes; modulators of the mitochondrial protein uncoupling protein 3 (UCP3); treating retinoid X receptor (RXR) modulated conditions; 2-(4-carboxy-5-methylpyrazol-1-yl)-4-(p-trifluoromethylphenyl)thiazole
04/15/2008US7358266 Cyclopropyl and cyclobutyl epothilone analogs
04/15/2008US7358265 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
04/15/2008US7358264 Statine derivatives for the treatment of Alzheimer's disease
04/15/2008US7358263 Fused bicyclic-substituted amines as histamine-3 receptor ligands
04/15/2008US7358262 Using transgenic tumor cells as models for antitumor agent efficacy; tissue targeted therapy and antiproliferative agents
04/15/2008US7358261 Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
04/15/2008US7358260 Quinuclidine derivatives and medicinal compositions containing the same
04/15/2008US7358259 Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide
04/15/2008US7358258 Prodrugs of an ERK protein kinase inhibitor
04/15/2008US7358257 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents
04/15/2008US7358256 Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide
04/15/2008US7358255 Use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl] thiazolidine-2,4-dione
04/15/2008US7358254 Method for treating atherosclerosis employing an aP2 inhibitor and combination
04/15/2008US7358253 Indolylmaleimide derivatives
04/15/2008US7358252 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever
04/15/2008US7358251 Bcl-XL inhibitors; N-{[4-({(1R)-5-(dimethylamino)-1-[(phenylthio)methyl]pentyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-fluorophenyl)piperidine-1-carboxamide; useful for promoting apoptosis; Anticancer agents; autoimmune diseases; antiinflammatory agents
04/15/2008US7358250 Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
04/15/2008US7358249 Heterocyclic compounds having inhibitory activity against HIV integrase
04/15/2008US7358248 treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatases
04/15/2008US7358247 Mycophenolate mofetil impurity
04/15/2008US7358246 5-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbothioamide; contraceptive, menopause; reduces risk of uterine cancers coused by treating with estrogen receptor (ER) agonists
04/15/2008US7358245 Administering a therapeutically effective amount of a compound which is a cannabinoid receptor agonist, a pharmaceutically acceptable salt of the compound, an isomer of the compound, or a pharmaceutically acceptable salt of the isomer
04/15/2008US7358244 Azabicycloalkane compounds
04/15/2008US7358243 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction
04/15/2008US7358242 N-benzyl-2-[4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b-tetraaza-benzo[e]azulen-6-yl]-N-isopropyl-acetamide; cholecystokinin-A (CCK-A) receptor agonist; antidiabetic; obesity
04/15/2008US7358240 excellent purity; bradycardic agent; myocardial ischaemia: angina pectoris, myocardial infarct, arrhythmia disturbances, heart failure; structure confirms by X-ray diffraction data; industrial scale, storage stability
04/15/2008US7358239 Treating impaired fundic relaxation; [1(R),[A-(3 alpha ,4 alpha )]]-1-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-3-methoxy-4-piperidinyl]-2(1H)-pyrimidinone
04/15/2008US7358238 3-(2-Phenoxymethyl-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]azepin-9-one; inhibiting the activity of 11 beta -hydroxysteroid dehydrogenase type 1 (11 beta HSD1); increase intracellular concentration of active glucocorticoid; metabolic disorders, insulin resistance, dyslipidemia, obesity
04/15/2008US7358236 Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
04/15/2008US7358235 Nitrobenzylthioinosine compounds for relief of pain
04/15/2008US7358234 Induction of a protective immune response through microprojectiles coated with a DNA sequence encoding an immunogenic protein
04/15/2008US7358233 Tetronic acid derivative
04/15/2008US7358232 Using aqueous solution of water soluble antibiotic and surfactant; vaporizatio, evaportaion of water; forming deposits
04/15/2008US7358231 Pancreatic cancer secreted targets and uses thereof
04/15/2008US7358226 The localized, targeted delivery of a drug or contrast agent for imaging by administering and concentrating a carrier by exposing it to a radiation force generated by ultrasound waves at a frequency and pressure combination; rupturing;affecting tissue permeability or altering cell physiology
04/15/2008US7358224 Class III SLRP agonists for the reduction of blood vessel formation
04/15/2008US7358222 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs
04/15/2008US7358214 [5-fluoro-1-methyl-3-(trifluoromethyl)pyrazol-4-yl]-N-[2-(1-hydroxy-1-methylhexyl)phenyl]carboxamide and its derivatives as bactericide, fungicide, herbicide
04/15/2008US7358086 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
04/15/2008US7358068 For use as therapeutic agents in viral infections by human and animal viruses and in cancers caused by oncogene viruses; non-sequence complementary mode of action; drug screening
04/15/2008US7358046 Sensitivity test to predict efficacy of anti-cancer therapies
04/15/2008US7358045 Using engrailed-2 (En-2) gene expression as a diagnostic and prognostic indicator of mammary gland cell proliferative disorders; antisense agents
04/15/2008US7357950 Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
04/15/2008US7357945 Oral dosage form contains povidone or copovidone binder; HCl-free or non-hygroscopic filler; serotonin reuptake inhibition; stable without lose its hardness after storage
04/15/2008US7357944 Liposomal analgesic drug compositions prepared in GMV using an ammonium sulfate gradient
04/15/2008US7357943 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
04/15/2008US7357942 For local delivery using a stent; reduced neointimal hyperplasia
04/15/2008US7357941 implanting matrix for bioactive material which is biocompatible porous forms of beta -tricalcium phosphate granules support the development of new bone throughout its structural form, together with bone morphogenic protein as bioactive material
04/15/2008US7357938 Sulfacetamide formulations for treatment of rosacea
04/15/2008US7357937 Stability; gas delivery agent used in cosmetic or therapeutic product
04/15/2008US7357931 Gene expression inhibition; drug screening; peroxisome proliferator-activated receptor agonists such as fenofibrate
04/15/2008US7357930 Methods and formulations for targeting infectious agents bearing host cell proteins
04/15/2008CA2566590C Cronotherapeutic diltiazem formulation and the administration thereof
04/15/2008CA2454027C Residual solvent extraction method and microparticles produced thereby
04/15/2008CA2411468C Thrombopoietin mimetics
04/15/2008CA2410985C Compositions and methods for body weight management
04/15/2008CA2410303C Beta-amino acid nitrile derivatives